The Latest Breaking News from FDA

Johnson Johnson (NYSE:JNJ) stock has surged almost 42.9% in the year to date, approximately 35% in 6 months, and 8.6% in one month.

The U.S. Food and Drug Administration (FDA) on Tuesday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Lower your dementia risk with this one hack.

Imagine carrying a device inside your chest that keeps you alive, yet could be accessed by hackers. Pacemakers and other connected medical devices are designed...

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.

Palvella Therapeutics (PVLA) is a clinical-stage biopharma stock with no revenue or FDA pipeline. However, the stock has exceptional price momentum with shares up 508% over the past year. PVLA is trading at a new 2-year high and has strong technical indicators. Palvella is highly speculative. It is suitable for...

ByHeart's voluntary recall of its infant formula this November has raised concerns after families reported babies falling ill months earlier, highlighting potential delays in outbreak detection and regulatory response.

Physicians say FDA panel conflated two issues and made baseless claims about unproven health benefits

The affected products were sold in 33 states across the U.S.